Fusion Protein Technologies for Biopharmaceuticals (eBook)

The state of the art in biopharmaceutical FUSION PROTEIN
DESIGN

Fusion proteins belong to the most lucrative biotech
drugs--with Enbrel® being one of the best-selling
biologics worldwide. Enbrel® represents a milestone of modern
therapies just as Humulin®, the first therapeutic recombinant
protein for human use, approved by the FDA in 1982 and
Orthoclone® the first monoclonal antibody reaching the market
in 1986. These first generation molecules were soon followed by a
plethora of recombinant copies of natural human proteins, and in
1998, the first de novo designed fusion protein was launched.

Fusion Protein Technologies for Biopharmaceuticals
examines the state of the art in developing fusion proteins for
biopharmaceuticals, shedding light on the immense potential
inherent in fusion protein design and functionality. A wide
pantheon of international scientists and researchers deliver a
comprehensive and complete overview of therapeutic fusion proteins,
combining the success stories of marketed drugs with the dynamic
preclinical and clinical research into novel drugs designed for as
yet unmet medical needs.

The book covers the major types of fusion
proteins--receptor-traps, immunotoxins, Fc-fusions and
peptibodies--while also detailing the approaches for
developing, delivering, and improving the stability of fusion
proteins. The main body of the book contains three large sections
that address issues key to this specialty: strategies for extending
the plasma half life, the design of toxic proteins, and utilizing
fusion proteins for ultra specific targeting. The book concludes
with novel concepts in this field, including examples of highly
relevant multifunctional antibodies.

Detailing the innovative science, commercial realities, and
brilliant potential of fusion protein therapeutics, Fusion
Protein Technologies for Biopharmaceuticals is a must for
pharmaceutical scientists, biochemists, medicinal chemists,
molecular biologists, pharmacologists, and genetic engineers
interested in determining the shape of innovation in the world of
biopharmaceuticals.